Abstract
Background/Aims: SM22α, transgelin, is abundantly expressed in smooth muscle tissues and our previous work demonstrated that it is a novel marker of injured glomerular epithelial cells in rat antiglomerular basement membrane nephritis. In this study, we investigated SM22α expression in models of glomerular and interstitial renal injury. Methods: The 5/6 nephrectomy (Nx) model, ischemia-reperfusion (I/R) model and puromycin aminonucleoside (PAN) nephrosis of rats were studied. Immunohistochemical analyses and immunoelectron microscopic studies of SM22α expression were performed. Results: In the 5/6 Nx model, SM22α was first expressed in peritubular interstitial cells and was also expressed in injured glomerular epithelial cells at 8 weeks. In the I/R model, SM22α expression was induced in peritubular interstitial cells as early as 12 h after I/R with expression sustained at 7 days. However, SM22α was not detected in any glomerular cells or tubular epithelial cells. In PAN nephrosis, SM22α was only expressed in glomerular epithelial cells after 1 week, but expression was transient. Conclusion: SM22α was expressed in glomerular epithelial cells and interstitial cells in renal injury. SM22α is differentially upregulated in various models of renal injury and merits further study.
References
1.
Assinder SJ, Stanton JA, Prasad PD: Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol 2009;41:482–486.
[PubMed]
2.
Duband JL, Gimona M, Scatena M, Sartore S, Small JV: Calponin and SM 22 as differentiation markers of smooth muscle: Spatiotemporal distribution during avian embryonic development. Differentiation 1993;55:1–11.
[PubMed]
3.
Pearlstone JR, Weber M, Lees-Miller JP, Carpenter MR, Smillie LB: Amino acid sequence of chicken gizzard smooth muscle SM22 alpha. J Biol Chem 1987;262:5985–5991.
[PubMed]
4.
Feil S, Hofmann F, Feil R: SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. Circ Res 2004;94:863–865.
[PubMed]
5.
Camoretti-Mercado B, Forsythe SM, LeBeau MM, Espinosa R 3rd, Vieira JE, Halayko AJ, Willadsen S, Kurtz B, Ober C, Evans GA, Thweatt R, Shapiro S, Niu Q, Qin Y, Padrid PA, Solway J: Expression and cytogenetic localization of the human SM22 gene (TAGLN). Genomics 1998;49:452–457.
[PubMed]
6.
Lawson D, Harrison M, Shapland C: Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997;38:250–257.
[PubMed]
7.
Ogawa A, Sakatsume M, Wang X, Sakamaki Y, Tsubata Y, Alchi B, Kuroda T, Kawachi H, Narita I, Shimizu F, Gejyo F: SM22alpha: the novel phenotype marker of injured glomerular epithelial cells in anti-glomerular basement membrane nephritis. Nephron Exp Nephrol 2007;106:e77–e87.
[PubMed]
8.
Bariety J, Bruneval P, Hill GS, Mandet C, Jacquot C, Meyrier A: Transdifferentiation of epithelial glomerular cells. J Am Soc Nephrol 2003;14(Suppl 1):S42–S47.
[PubMed]
9.
Drenckhahn D, Franke RP: Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest 1988;59:673–682.
[PubMed]
10.
Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B: Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007;323:85–93.
[PubMed]
11.
Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B: Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 2008;294:F336–F344.
[PubMed]
12.
Zhang B, Liang X, Shi W, Ye Z, He C, Hu X, Liu S: Role of impaired peritubular capillary and hypoxia in progressive interstitial fibrosis after 56 subtotal nephrectomy of rats. Nephrology (Carlton) 2005;10:351–357.
[PubMed]
13.
Santos LS, Chin EW, Ioshii SO, Tambara Filho R: Surgical reduction of the renal mass in rats: morphologic and functional analysis on the remnant kidney. Acta Cir Bras 2006;21:252–257.
[PubMed]
14.
Schwartz MM, Bidani AK, Lewis EJ: Glomerular epithelial cell function and pathology following extreme ablation of renal mass. Am J Pathol 1987;126:315–324.
[PubMed]
15.
Forbes JM, Hewitson TD, Becker GJ, Jones CL: Ischemic acute renal failure: long-term histology of cell and matrix changes in the rat. Kidney Int 2000;57:2375–2385.
[PubMed]
16.
Furuichi K, Gao JL, Murphy PM: Chemokine receptor cx3cr1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 2006;169:372–387.
[PubMed]
17.
Basile DP, Donohoe D, Roethe K, Osborn JL: Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001;281:F887–F899.
[PubMed]
18.
Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G: Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int 2002;61:2066–2077.
[PubMed]
19.
Zhang G, Moorhead PJ, el Nahas AM: Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol 1995;3:308–318.
[PubMed]
20.
Muchaneta-Kubara EC, el Nahas AM: Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 1997;12:904–915.
[PubMed]
21.
Kawachi H, Koike H, Shimizu F: Molecular structure and function of the slit diaphragm: expression of nephrin in proteinuric states and in developing glomeruli. Nephrol Dial Transplant 2002;17(Suppl 9):20–22.
[PubMed]
22.
Yaoita E, Kawasaki K, Yamamoto T, Kihara I: Variable expression of desmin in rat glomerular epithelial cells. Am J Pathol 1990;136:899–908.
[PubMed]
23.
Saga D, Sakatsume M, Ogawa A, Tsubata Y, Kaneko Y, Kuroda T, Sato F, Ajiro J, Kondo D, Miida T, Narita I, Gejyo F: Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis. Kidney Int 2005;67:1821–1829.
[PubMed]
24.
Tsubata Y, Sakatsume M, Ogawa A, Alchi B, Kaneko Y, Kuroda T, Kawachi H, Narita I, Yamamoto T, Gejyo F: Expression of allograft inflammatory factor-1 in kidneys: a novel molecular component of podocyte. Kidney Int 2006;70:1948–1954.
[PubMed]
25.
Xie Y, Nishi S, Iguchi S, Imai N, Sakatsume M, Saito A, Ikegame M, Iino N, Shimada H, Ueno M, Kawashima H, Arakawa M, Gejyo F: Expression of osteopontin in gentamicin-induced acute tubular necrosis and its recovery process. Kidney Int 2001;59:959–974.
[PubMed]
26.
Sakatsume M, Kadomura M, Sakata I, Imai N, Kondo D, Osawa Y, Shimada H, Ueno M, Miida T, Nishi S, Arakawa M, Gejyo F: Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney International 2001;59:1911–1918.
[PubMed]
27.
Yu H, Konigshoff M, Jayachandran A, Handley D, Seeger W, Kaminski N, Eickelberg O: Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J 2008;22:1778–1789.
[PubMed]
28.
Bottinger EP, Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13:2600–2610.
[PubMed]
29.
Qiu P, Feng XH, Li L: Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003;35:1407–1420.
[PubMed]
30.
Qiu P, Ritchie RP, Gong XQ, Hamamori Y, Li L: Dynamic changes in chromatin acetylation and the expression of histone acetyltransferases and histone deacetylases regulate the SM22alpha transcription in response to Smad3-mediated TGFbeta1 signaling. Biochem Biophys Res Commun 2006;348:351–358.
[PubMed]
31.
Zou J, Yaoita E, Watanabe Y, Yoshida Y, Nameta M, Li H, Qu Z, Yamamoto T: Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch 2006;448:485–492.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
